May 9 |
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores
|
Apr 9 |
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
|
Apr 4 |
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
|
Mar 28 |
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
|
Mar 27 |
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
|
Feb 10 |
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
Feb 8 |
Sonoma Pharmaceuticals GAAP EPS of -$0.08 beats by $0.13, revenue of $3.14M misses by $0.62M
|
Feb 8 |
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
|
Jan 23 |
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
|
Jan 9 |
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
|